Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx in participants with high lipoprotein(a).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Elevated Lipoprotein

Drugs mentioned

• ISIS-APO(a)Rx (antisense oligonucleotide targeting Apo(a))

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Elevated Lipoprotein(a) | Phase 2 | Status: COMPLETED | Results posted: 2019-12-20